Skip to main content

Adicet Bio, Inc.

ACET
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001720580

No open-market purchases or sales by Adicet Bio, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $52.8M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Adicet Bio, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of ACET: Q3 2023 compared with Q4 2023
MeasureQ3 2023Of which not filed for Q4 2023Q4 2023Change
Holders84177−6
Shares35.7M200.2K33.4M−2.11M (−5.9%)
Value$48.9M$274.3K$63.0M+$14.5M (+29.8%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held Adicet Bio, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to ACET in Q4 2023
InstitutionSharesValue% of portfolio
Schonfeld Strategic Advisors LLC200,100$378.2K0.00%
Panagora Asset Management Inc51,746$97.8K0.00%
SEI Investments Co31,012$58.6K0.00%
Jane Street Group, LLC23,012$43.5K0.00%
Wexford Capital LP14,930$28.2K0.01%
Invesco Ltd.10,446$19.7K0.00%
GAMMA Investing LLC3,829$11.4K0.00%
Northwest Financial Advisors1,685$3.19K0.00%

Sold out (14)

Institutions that held Adicet Bio, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Not filed for Q4 2023 yet (1)

Institutions that held Adicet Bio, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ACET in Q3 2023 that haven't filed for Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Decheng Capital Management III (Cayman), LLC200,201$274.3K